<DOC>
	<DOC>NCT00269113</DOC>
	<brief_summary>This 2 arm study will compare the efficacy and safety of the standard chemotherapy of the East German Study Group for Hematology and Oncology versus standard chemotherapy plus MabThera (375mg/m2 iv, once monthly for 8 cycles) in patients with indolent non-Hodgkin's and mantle cell lymphoma. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patients &gt;=18 years of age; advanced, lowgrade nonHodgkin's and mantle cell lymphoma. possibility of curative radiation therapy; secondary NHL; participation in another clinical trial eg with cytostatic chemotherapy or cytokines; concomitant diseases and/or restricted organ function precluding therapy according to the study protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>